How Big is the GLP-1 Agonist Market | Growth Analysis & Insights 2026

Q: How big is the GLP-1 agonist market?

The GLP-1 agonist market was estimated at USD 18.9 billion in 2024 and is projected to reach USD 42.98 billion by 2031.

Q: What is the growth rate of the GLP-1 agonist market?

The GLP-1 agonist market is expected to grow at a CAGR of 13% during 2025–2031.

Q: What drives the demand for GLP-1 agonists?

Rising diabetes and obesity cases, along with therapeutic innovations, are the primary growth drivers.

Q: Who are the key players in the GLP-1 agonist market?

GLP-1 agonist market players include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6817

Publication Date: Jul 2025

What is the size of GLP-1 Agonist Market?

According to 6Wresearch internal database and industry insights, the GLP-1 Agonist Market was estimated at USD 18.9 billion in 2025 and is projected to reach USD 42.98 billion by 2032, growing at a CAGR of 13% during the forecast period 2026–2032.

Due to rising cases of type 2 diabetes and obesity, coupled with growing acceptance of GLP-1 agonists in chronic disease management, the GLP-1 agonist market is predicted for the robust growth in the coming years.

Key Growth Drivers of the GLP-1 Agonist Market

Rising global prevalence of type 2 diabetes and obesity
Increased awareness and adoption of novel injectable therapies
Favourable reimbursement policies and clinical efficacy in glycaemic control
Expansion of applications beyond diabetes, including obesity and cardiovascular health
Product innovation with long-acting formulations and oral GLP-1 drugs

GLP-1 Agonist Market Trends

GLP-1 market is growing over the years with notable trends such as rising shift towards once-weekly and oral GLP-1 agonists for improved patient compliance. The focus is emphasizing on weight management indications, driving demand from both diabetic and non-diabetic populations. Combination therapies, such as GLP-1 with SGLT2 inhibitors, are gaining momentum. Major players are investing in clinical trials for cardiovascular and metabolic syndrome applications. Telehealth and digital platforms are supporting drug adherence and remote prescription.

Emerging Developments in the GLP-1 Agonist Market

GLP-1 market is being advanced with the time which include the development of dual and triple agonists combining GLP-1, GIP, and glucagon receptors for enhanced metabolic control. Oral GLP-1 drugs with higher bioavailability are under clinical trials. Also, research is expanding into Alzheimer’s, NASH, and PCOS treatments using GLP-1 pathways. Further, digital therapeutics and companion apps are being introduced to monitor patient outcomes. Business strategic partnerships are accelerating global market penetration and drug access.